PXN and ovarian cancer: To further investigate the roles of FAK/Paxillin signaling pathway and the alterations of downstream signaling proteins in the inhibition of ovarian cancer cell transformation exerted by lidocaine, the reduced p‐FAK levels were determined by FAK siRNAs (−1, −2, and −3) transfection and addition of FAK inhibitor (FAKi) (PF‐562271, Selleck Chemicals, Huston, USA) in different concentrations (1, 5, and 10 μM) by western blot (Figure 5C,D), and FAK siRNA‐1 and FAKi (5 μM) were selected for further study.